ZLNA ZELLUNA ASA

Disclosure of Shareholding – Gjelsten Holding AS

Disclosure of Shareholding – Gjelsten Holding AS

Issuer: Zelluna ASA

ISIN: NO0013524942

Date of event triggering the notification: 27 May 2025

Threshold crossed: 5%

In accordance with the Norwegian Securities Trading Act Section 4-3, Gjelsten Holding AS ("Gjelsten") hereby notifies that its ownership interest in Zelluna ASA ("Zelluna") has fallen below the 5% threshold. Following a share capital increase in Zelluna through a private placement registered in VPS on 27 May 2025, Gjelsten’s ownership has changed as follows:

  • Previous shareholding: 5.02% of the share capital
  • New shareholding: 4.96% of the share capital
  • Total number of shares held: 1,014,972 shares



The reduction in ownership is due to dilution as a result of the private placement. Gjelsten has not sold any shares.

This notification is submitted pursuant to Section 4-3 of the Norwegian Securities Trading Act and the Oslo Rule Book II – Issuer Rules.



EN
27/05/2025

Underlying

ZLNAZELLUNA ASA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ZELLUNA ASA

 PRESS RELEASE
Free
ZLNA ZELLUNA ASA

Disclosure of Shareholding – Gjelsten Holding AS

Disclosure of Shareholding – Gjelsten Holding AS Issuer: Zelluna ASAISIN: NO0013524942Date of event triggering the notification: 27 May 2025Threshold crossed: 5% In accordance with the Norwegian Securities Trading Act Section 4-3, Gjelsten Holding AS ("Gjelsten") hereby notifies that its ownership interest in Zelluna ASA ("Zelluna") has fallen below the 5% threshold. Following a share capital increase in Zelluna through a private placement registered in VPS on 27 May 2025, Gjelsten’s ownership has changed as follows: Previous shareholding: 5.02% of the share capitalNew shareholding: 4.96%...

May 27, 2025 1 EN
 PRESS RELEASE
Free
ZLNA ZELLUNA ASA

ZLNA – New registered share capital

ZLNA – New registered share capital Oslo, 27 May 2025: Zelluna ASA (the "Company") refers to the announcement on 24 May 2025 regarding a resolution by the Company's Board of Directors to issue 227,096 new shares in the Company against set-off of an option exercise fee. The share capital increase related to the issuance of the new shares has now been registered with the Norwegian Register of Business Enterprises, and the Company's new registered share capital is NOK 20,454,162, divided into 20,454,162 shares, each with a par value of NOK 1. For further information, please contact: Hans V...

May 27, 2025 1 EN
 PRESS RELEASE
Free
ZLNA ZELLUNA ASA

ZLNA – Issuance of shares through set-off of option exercise fee

ZLNA – Issuance of shares through set-off of option exercise fee Oslo, 24 May 2025: Zelluna ASA (the "Company") refers to the resolution by the Company's Annual General Meeting held on 29 April 2025 to grant the Company's Board of Directors an authorisation to issue new shares, each with a subscription price of NOK 26, to settle an amount of EUR 500,000 of an already triggered option exercise fee towards Inven2. The Company's Board of Directors has today resolved to issue 227,096 new shares in the Company to Inven2 against set-off of such amount of EUR 500,000. After the share capital incr...

May 24, 2025 1 EN
 PRESS RELEASE
Free
ZLNA ZELLUNA ASA

Zelluna ASA Reports First Quarter 2025 Financial Results and Provides ...

Zelluna ASA Reports First Quarter 2025 Financial Results and Provides General Business Update Oslo, Norway, 8 May 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic ‘off the shelf’ T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer, announces its first quarter 2025 results today. Conference call and webcast scheduled for 8 May, 2025, at 09:00 (CET). Link to webcast . First Quarter 2025 Business Update Highlights On 3 March 2025, Zelluna ASA announced the successful completion of a business combination between Ultimovacs ASA and Zelluna Immuno...

May 8, 2025 1 EN
 PRESS RELEASE
Free
ZLNA ZELLUNA ASA

Zelluna ASA: Invitation to First Quarter 2025 results webcast presenta...

Zelluna ASA: Invitation to First Quarter 2025 results webcast presentation Oslo, Norway, 30 April 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic ‘off the shelf’ T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer, invites to a webcast presentation of its first quarter 2025 results, on Thursday, May 8, 2025. The presentation can be followed as a live webcast accessed through a link on at 09:00 CET on Thursday, May 8, 2025. The webcast presentation will be available on the Zelluna website, and it will be possible to post questions during the presenta...

April 30, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch